Improving Collection and Analysis of Overall Survival Data
Lisa R Rodriguez,Nicole J Gormley,Ruixiao Lu,Anup K Amatya,George D Demetri,Keith T Flaherty,Ruben A Mesa,Richard Pazdur,Mikkael A Sekeres,Minghua Shan,Steven Snapinn,Marc R Theoret,Rukiya Umoja,Jonathon Vallejo,Nicholas J H Warren,Qing Xu,Kenneth C Anderson
DOI: https://doi.org/10.1158/1078-0432.CCR-24-0919
2024-09-13
Abstract:Advances in anticancer therapies have provided crucial benefits for millions of patients who are living long and fulfilling lives. Although these successes should be celebrated, there is certainly room to continue improving cancer care. Increased long-term survival presents additional challenges for determining whether new therapies further extend patients' lives through clinical trials, commonly known as the gold standard endpoint of overall survival (OS). As a result, an increasing reliance is observed on earlier efficacy endpoints, which may or may not correlate with OS, to continue the timely pace of translating innovation into novel therapies available for patients. Even when not powered as an efficacy endpoint, OS remains a critical indication of safety for regulatory decisions and is a key aspect of the FDA's Project Endpoint. Unfortunately, in the pursuit of earlier endpoints, many registrational clinical trials lack adequate planning, collection, and analysis of OS data, which complicates interpretation of a net clinical benefit or harm. This article shares best practices, proposes novel statistical methodologies, and provides detailed recommendations to improve the rigor of using OS data to inform benefit-risk assessments, including incorporating the following in clinical trials intending to demonstrate the safety and effectiveness of cancer therapy: prospective collection of OS data, establishment of fit-for-purpose definitions of OS detriment, and prespecification of analysis plans for using OS data to evaluate for potential harm. These improvements hold promise to help regulators, patients, and providers better understand the benefits and risks of novel therapies.